In its Q1 2026 filing, Contineum Therapeutics reported initiation of a Phase 2 clinical trial for PIPE-791 targeting idiopathic pulmonary fibrosis, alongside promising Phase 1b chronic pain data expected imminently. The partner-led PIPE-307 program under Johnson & Johnson exhibits mixed Phase 2 results, with J&J retaining sole discretion over future development. The firm's proprietary focus on selective small molecules for neuroinflammation and immunology, coupled with a strategic alliance and manufacturing outsourcing, underpin its developmental progress in a competitive and capital-intensive sector. Significant risks remain tied to clinical outcomes and regulatory pathways, balanced by solid liquidity and measured operating cash use.